Quarterly report [Sections 13 or 15(d)]

Significant Strategic Collaborations (Details Narrative)

v3.25.1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended
Mar. 17, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   $ 593,261 $ 510,817  
Research and development expenses   879,029 944,321  
Advance payment and included within prepaid expenses and other current assets   313,620   $ 421,954
Revenues   593,261 510,817  
Collaborative Agreements [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   0 0  
Takeda [Member] | Royalty Revenue [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   600,000 500,000  
Catalent Pharma Solutions [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses   2,500,000    
Advance payment and included within prepaid expenses and other current assets   28,000   28,000
Liability and included in accrued expenses and other current liabilities   100,000   100,000
Other assets   300,000   $ 300,000
Scripps Research [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses $ 900,000      
Scripps Research [Member] | Scripps Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses   900,000    
Prepaid expenses and other   400,000    
University Of Virginia [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses   400,000 $ 0  
Advance payment and included within prepaid expenses and other current assets   $ 100,000